Cidara Therapeutics (CDTX) announced updates to its planned Phase 3 registrational trial of CD388 following its End-of-Phase 2, EOP2, meeting with the U.S. Food and Drug Administration, FDA. Cidara is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback